One Patent Tossed, Two Upheld In Celebrex Appeal
Teva had sought to overturn a lower court's ruling that its generic product had infringed on all three patents.
The U.S. Court of Appeals for the Federal Circuit decision, handed down Friday, bars Teva from launching a generic version of Celebrex in the U.S. until May 2014. Either party...
To view the full article, register now.